Abstract. Cirrhotic 
Abstract. Cirrhotic patients reportedly show alterations of anterior pituitary hormone secretion, which may reflect an underlying defective central neurotransmitter function. In this study, we have investigated the catecholaminergic control of prolactin (Prl) and growth hormone (GH) secretion in cirrhotic patients by means of an indirectly acting dopamine (DA) and norepinephrine agonist, nomifensine (Nom), and a DA receptor antagonist, domperidone (Dom) . Basal GH levels were higher in the 12 female and male cirrhotic patients than in the 12 age-and sex-matched normal controls, while no (Cameron et al. 1972; Van Thiel et al. 1975 . In addition, most of them exhibit an anomalous GH response to administration of thyrotrophin-releasing hormone (TRH) and a pa¬ radoxical plasma GH rise after glucose loading (Panerai et al. 1977; Becker et al. 1969 ). These abnormalities of AP hormone secretion may be due to defective function of central neurotransmitters including dopamine (DA), a deficiency of which has been postulated on the basis of biochemical studies in rodents and humans (James et al. 1976; Baldessarini & Fisher 1977 (Borzio et al. 1981) .
In the present study, we decided to investigate the function of the hypothalamic dopaminergic system by evaluating Prl secretion in cirrhotic pa¬ tients, after administration of the indirect DA agonist nomifensine (Nom) and the DA receptor blocker domperidone (Dom), two drugs whose effect on Prl secretion is dependent upon the functional integrity of the tubero-infundibular do¬ paminergic (TIDA) system (Müller et al. 1981 (Braestrup & Scheel-Krüger 1976; Algeri et al. 1982) , but has no effect on post-synaptic DA receptors (Casanueva et al. 1982) . Similarly, Nom does not inhibit Prl secretion in subjects with a prolactinoma patients with a prolactinoma ).
Nom induces a consistent inhibition of Prl levels in normal women when the basal values of the hormone are sufficiently high (> 12 ng/ml) but has little effect on Prl levels in normal women with very low baseline Prl values, or in men ).
In view of these findings the inability of Nom to decrease Prl secretion in some cirrhotic patients does not necessarily indicate defective hypothal¬ amic dopaminergic function. In fact, the drug was also inactive in this respect in 6 controls, and, moreover, it has been shown by us that normal women are hyporesponsive to Nom with advancing age ; interestingly, 3 of the Nom non-responder patients were post-menopausal women.
In support of this proposition Dom was able to increase Prl levels to a similar extent in the cirrhotic and control subjects, which should denote the intact TIDA neuronal function.
Further evidence favouring preserved TIDA neuronal function was that all our patients had basal Prl levels no higher than the controls. At variance with other groups (Tarquini et al. 1977; Van Thiel et al. 1978) who reported increased Prl secretion in some cirrhotic patients, coupled to unresponsiveness to TRH, we also found normal Prl levels in most patients in our previous series (80 cirrhotic patients) . Only 3 patients in the preceding study (Salerno et (Müller 1979) ; 2) differing pharmacokinetics of the drug in cirrhotic patients. The first hypothesis seems unlikely since L-dopa, which also activates catecholaminergic neurons, has been reported to induce similar increases in pa¬ tients and controls or to be ineffective in cirrhotic patients (Borzio et al. 1981 (Müller 1979) . Unlike that on GH, the action of Nom on Prl is mainly exerted on (TIDA) nerve terminals of the median eminence (Apud et al. 1980) , where the BBB is lacking, and would not be impaired by a different bioavariability of the drug.
Supporting this view, is the fact that the time course of the Prl inhibition by Nom in responder subjects was the same for cirrhotic patients and for controls.
In conclusion, normal Prl responsiveness to Nom and Dom would suggest the existence of preserved TIDA neuronal function, at least in the group of cirrhotic patients investigated in this study.
In contrast to Prl, GH responsiveness to Nom was greatly enhanced in cirrhotic patients, a fact which might be due to a different bioavailability of the drug or to hyperfunction of the hypothalamic noradrenergic system.
